Cargando…
PRO: Biomarker surveillance for invasive fungal infections without antifungal prophylaxis could safely reduce antifungal use in acute leukaemia
Mould-active antifungal prophylaxis is frequently used to prevent invasive fungal infection in patients with acute leukaemia being treated with intensive chemotherapy. Invasive fungal infections are difficult to diagnose, and despite the use of prophylaxis a high proportion of patients still receive...
Autores principales: | Taynton, Thomas, Barlow, Gavin, Allsup, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305519/ https://www.ncbi.nlm.nih.gov/pubmed/35873180 http://dx.doi.org/10.1093/jacamr/dlac074 |
Ejemplares similares
-
CON: Serum biomarker monitoring should not replace primary antifungal
chemoprophylaxis in patients with acute leukaemia receiving systemic anti-cancer
therapy
por: Howard, Alex, et al.
Publicado: (2022) -
P10 Biomarker Driven Antifungal Stewardship in Acute Leukaemia (BioDriveAFS)—a multicentre randomized controlled trial to assess clinical and cost effectiveness
por: Taynton, Thomas, et al.
Publicado: (2022) -
Benefits of risk‐adapted and mould‐specific antifungal prophylaxis in childhood leukaemia
por: Meryk, Andreas, et al.
Publicado: (2020) -
Antifungal Prophylaxis
por: Johnson, Douglas Clark, et al.
Publicado: (2021) -
Reply: Antifungal Prophylaxis
por: Pennington, Kelly M., et al.
Publicado: (2021)